logo
Plus   Neg
Share
Email

BNY Mellon Q4 Profit Halves, But Results Top Estimates - Quick Facts

Bank of New York Mellon Corp. (BK) reported Wednesday that net income applicable to common shareholders for the fourth quarter halved to $702 million or $0.79 per share from $1.39 billion or $1.52 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter were $861 million or $0.96 per share, compared to $931 million or $1.01 per share in the year-ago quarter.

Total revenue for the quarter decreased 20 percent to $3.84 billion from $4.78 billion in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.91 per share on revenue of $3.83 billion for the quarter. Analysts' estimates typically exclude certain special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has filed a lawsuit against Texas Attorney General Ken Paxton, seeking to halt his ongoing investigation into the company's content moderation practices. Paxton, a Republican and supporter of former president Donald Trump, on January 13 had sent a civil investigative demand or CID to Twitter after its decision to permanently suspend Trump from the social media platform... The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine
Follow RTT